Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Down 7.5%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)’s share price was down 7.5% during mid-day trading on Thursday . The company traded as low as $18.76 and last traded at $19.23. Approximately 142,592 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 4,136,076 shares. The stock had previously closed at $20.79.

A number of research analysts recently issued reports on AUPH shares. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 17th. SVB Leerink restated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, August 19th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Aurinia Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $27.33.

The firm’s 50-day moving average is $15.07 and its 200 day moving average is $13.64. The stock has a market cap of $2.70 billion, a PE ratio of -19.09 and a beta of 0.48.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Wednesday, August 4th. The biotechnology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 242.26% and a negative return on equity of 36.98%. The business had revenue of $6.62 million during the quarter, compared to analysts’ expectations of $4.98 million. Equities research analysts anticipate that Aurinia Pharmaceuticals Inc. will post -1.34 EPS for the current fiscal year.

In other Aurinia Pharmaceuticals news, EVP Robert Bindert Huizinga sold 10,000 shares of the business’s stock in a transaction on Friday, September 10th. The shares were sold at an average price of $19.80, for a total value of $198,000.00. Following the transaction, the executive vice president now directly owns 133,592 shares of the company’s stock, valued at approximately $2,645,121.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael Robert Martin sold 5,000 shares of the business’s stock in a transaction on Tuesday, June 22nd. The shares were sold at an average price of $13.76, for a total transaction of $68,800.00. Following the completion of the transaction, the insider now directly owns 216,861 shares in the company, valued at $2,984,007.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 167,500 shares of company stock valued at $3,386,875. 3.10% of the stock is owned by insiders.

Several large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter worth $870,000. Parametric Portfolio Associates LLC grew its stake in shares of Aurinia Pharmaceuticals by 24.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 32,796 shares of the biotechnology company’s stock worth $425,000 after purchasing an additional 6,462 shares during the period. Morgan Stanley grew its stake in shares of Aurinia Pharmaceuticals by 1,080.9% during the 2nd quarter. Morgan Stanley now owns 3,621,692 shares of the biotechnology company’s stock worth $46,936,000 after purchasing an additional 3,315,006 shares during the period. Northern Oak Wealth Management Inc. grew its stake in shares of Aurinia Pharmaceuticals by 60.0% during the 2nd quarter. Northern Oak Wealth Management Inc. now owns 4,800 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 1,800 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Aurinia Pharmaceuticals by 3.2% during the 2nd quarter. Wells Fargo & Company MN now owns 788,283 shares of the biotechnology company’s stock worth $10,216,000 after purchasing an additional 24,462 shares during the period. 38.27% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Featured Story: What Are Cryptocurrencies?

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.